From the Catastrophic Objective Irreproducibility of Cancer Research and Unavoidable Failures of Molecular Targeted Therapies to the Sparkling Hope of Supramolecular Targeted Strategies.

Irina Alekseenko, Liya Kondratyeva, Igor Chernov, Eugene Sverdlov
Author Information
  1. Irina Alekseenko: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.
  2. Liya Kondratyeva: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia. ORCID
  3. Igor Chernov: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia. ORCID
  4. Eugene Sverdlov: National Research Center "Kurchatov Institute", 123182 Moscow, Russia.

Abstract

The unprecedented non-reproducibility of the results published in the field of cancer research has recently come under the spotlight. In this short review, we try to highlight some general principles in the organization and evolution of cancerous tumors, which objectively lead to their enormous variability and, consequently, the irreproducibility of the results of their investigation. This heterogeneity is also extremely unfavorable for the effective use of molecularly targeted medicine. Against the seemingly comprehensive background of this heterogeneity, we single out two supramolecular characteristics common to all tumors: the clustered nature of tumor interactions with their microenvironment and the formation of biomolecular condensates with tumor-specific distinctive features. We suggest that these features can form the basis of strategies for tumor-specific supramolecular targeted therapies.

Keywords

References

  1. Biomolecules. 2022 Sep 26;12(10): [PMID: 36291586]
  2. Comput Struct Biotechnol J. 2021 Jun 29;19:3964-3977 [PMID: 34377363]
  3. Exp Mol Med. 2022 Oct;54(10):1670-1694 [PMID: 36224343]
  4. Nat Rev Cancer. 2021 Sep;21(9):592-604 [PMID: 34239104]
  5. Expert Rev Mol Diagn. 2020 Nov;20(11):1139-1147 [PMID: 33140979]
  6. Cell. 2014 Aug 28;158(5):1110-1122 [PMID: 25171411]
  7. Immunol Rev. 2013 Nov;256(1):203-21 [PMID: 24117823]
  8. Biochemistry (Mosc). 2009 Sep;74(9):939-44 [PMID: 19916904]
  9. Cancers (Basel). 2019 Oct 16;11(10): [PMID: 31623163]
  10. Dev Cell. 2020 Oct 12;55(1):30-44 [PMID: 32726575]
  11. Immunity. 2016 Mar 15;44(3):463-475 [PMID: 26982354]
  12. Trends Pharmacol Sci. 2019 Jun;40(6):419-429 [PMID: 31078320]
  13. Nat Rev Mol Cell Biol. 2020 Dec;21(12):750-764 [PMID: 33093672]
  14. Noncoding RNA. 2019 Nov 01;5(4): [PMID: 31683819]
  15. Nat Cancer. 2021 Dec;2(12):1406-1422 [PMID: 35121907]
  16. Cold Spring Harb Perspect Biol. 2012 Aug 01;4(8):a005975 [PMID: 22855721]
  17. Mediators Inflamm. 2017;2017:9624760 [PMID: 28210073]
  18. Nat Med. 2021 Feb;27(2):212-224 [PMID: 33574607]
  19. Semin Cancer Biol. 2018 Oct;52(Pt 2):1-11 [PMID: 29428479]
  20. Cancer Res. 2008 May 15;68(10):3551-7; discussion 3557 [PMID: 18483233]
  21. Adv Funct Mater. 2021 Jan 27;31(5): [PMID: 33692665]
  22. Front Genet. 2021 Mar 22;12:617282 [PMID: 33828580]
  23. Biomed Res Int. 2018 Nov 1;2018:6304701 [PMID: 30515411]
  24. Adv Exp Med Biol. 2020;1220:11-34 [PMID: 32304077]
  25. Trends Biochem Sci. 2019 Aug;44(8):716-728 [PMID: 31023505]
  26. Int J Mol Sci. 2019 Sep 12;20(18): [PMID: 31547237]
  27. Cell Prolif. 2021 Feb;54(2):e12970 [PMID: 33336467]
  28. Mol Cell Biol. 2007 Dec;27(24):8583-99 [PMID: 17923698]
  29. Nat Rev Cancer. 2006 Dec;6(12):924-35 [PMID: 17109012]
  30. Front Endocrinol (Lausanne). 2019 Feb 18;10:53 [PMID: 30833931]
  31. Cold Spring Harb Perspect Biol. 2009 Jul;1(1):a002873 [PMID: 20066081]
  32. Circ Res. 2015 Jan 2;116(1):116-26 [PMID: 25552691]
  33. Oncogene. 2022 Mar;41(11):1527-1535 [PMID: 35132182]
  34. Drug Discov Today. 2021 Jan;26(1):189-199 [PMID: 33075471]
  35. Cells. 2019 Jun 06;8(6): [PMID: 31174404]
  36. Trends Cell Biol. 2020 Jan;30(1):4-14 [PMID: 31753533]
  37. Cell. 2011 Mar 4;144(5):646-74 [PMID: 21376230]
  38. Cold Spring Harb Perspect Med. 2020 Apr 1;10(4): [PMID: 31501262]
  39. Annu Rev Pathol. 2010;5:51-75 [PMID: 19743960]
  40. Nature. 2022 Dec;612(7940):577-579 [PMID: 36513832]
  41. Int J Mol Sci. 2021 Mar 04;22(5): [PMID: 33806300]
  42. Cancer Res. 2019 Jun 15;79(12):3011-3027 [PMID: 31053634]
  43. Semin Immunol. 2005 Dec;17(6):400-10 [PMID: 16266811]
  44. Tissue Barriers. 2021 Jan 2;9(1):1848212 [PMID: 33300427]
  45. Cancers (Basel). 2019 Mar 01;11(3): [PMID: 30823688]
  46. Immunol Rev. 2008 Feb;221:77-89 [PMID: 18275476]
  47. Cell. 2020 Apr 16;181(2):228-230 [PMID: 32302565]
  48. Cancers (Basel). 2022 Mar 25;14(7): [PMID: 35406451]
  49. Curr Gene Ther. 2011 Dec;11(6):501-31 [PMID: 22023469]
  50. Curr Opin Cell Biol. 2021 Apr;69:111-119 [PMID: 33578289]
  51. J Cell Sci. 2021 Feb 17;134(4): [PMID: 33597156]
  52. J Mol Med (Berl). 2022 Oct;100(10):1427-1440 [PMID: 36085373]
  53. Elife. 2021 Dec 07;10: [PMID: 34874009]
  54. J Hematol Oncol. 2021 Oct 21;14(1):173 [PMID: 34674757]
  55. J Mol Med (Berl). 2013 Apr;91(4):411-29 [PMID: 23515621]
  56. Commun Biol. 2020 Dec 15;3(1):773 [PMID: 33319830]
  57. Transl Cancer Res. 2021 Nov;10(11):4929-4946 [PMID: 35116344]
  58. Adv Virus Res. 2021;109:105-134 [PMID: 33934825]
  59. Adv Exp Med Biol. 2021;1341:177-192 [PMID: 30969400]
  60. Cancers (Basel). 2022 Apr 05;14(7): [PMID: 35406602]
  61. Dev Cell. 2015 Oct 12;35(1):12-20 [PMID: 26460944]
  62. Cancer Cell. 2021 Feb 8;39(2):174-192 [PMID: 33417833]
  63. Front Immunol. 2016 Jan 28;7:18 [PMID: 26858721]
  64. Annu Rev Biomed Eng. 2019 Jun 4;21:365-393 [PMID: 30883211]
  65. Clin Exp Metastasis. 2019 Apr;36(2):71-86 [PMID: 30847799]
  66. Curr Opin Cell Biol. 2021 Jun;70:58-66 [PMID: 33385708]
  67. Analyst. 2019 Jan 28;144(3):846-858 [PMID: 30351310]
  68. PLoS Comput Biol. 2007 Nov;3(11):e225 [PMID: 17997597]
  69. J Immunol. 2006 Aug 15;177(4):2349-55 [PMID: 16887996]
  70. Front Cell Dev Biol. 2016 May 04;4:36 [PMID: 27200348]
  71. Cell. 2010 Jun 25;141(7):1117-34 [PMID: 20602996]
  72. Biomed Res Int. 2022 Jul 4;2022:1012684 [PMID: 35832854]
  73. Nat Rev Mol Cell Biol. 2017 May;18(5):285-298 [PMID: 28225081]
  74. Curr Opin Cell Biol. 2013 Feb;25(1):85-91 [PMID: 22990072]
  75. Front Med (Lausanne). 2017 Apr 10;4:39 [PMID: 28443282]
  76. Curr Opin Struct Biol. 2020 Apr;61:79-85 [PMID: 31862615]
  77. Cancer Discov. 2019 Jan;9(1):22-24 [PMID: 30626605]
  78. Immunotherapy. 2018 Aug;10(10):899-909 [PMID: 30073897]
  79. Biochem Soc Trans. 2020 Dec 18;48(6):2591-2602 [PMID: 33300985]
  80. Biomed Res Int. 2017;2017:9042851 [PMID: 28691037]
  81. Mol Cancer Res. 2017 Sep;15(9):1127-1137 [PMID: 28596419]
  82. Nat Rev Cancer. 2022 Apr;22(4):239-252 [PMID: 35149762]
  83. Chem Rev. 2022 Mar 23;122(6):6719-6748 [PMID: 35179885]
  84. Cell. 2021 May 13;184(10):2649-2664.e18 [PMID: 33848463]
  85. Nature. 2021 Dec;600(7889):368-369 [PMID: 34887584]
  86. Trends Genet. 2021 Mar;37(3):224-234 [PMID: 32921511]
  87. Front Genet. 2019 Aug 06;10:713 [PMID: 31447882]
  88. Cancer Sci. 2020 Feb;111(2):467-476 [PMID: 31845453]
  89. Nature. 2022 Jan;601(7892):167 [PMID: 35017708]
  90. Proteomics. 2018 Feb;18(3-4): [PMID: 29316255]
  91. Cancer Treat Res Commun. 2022;32:100592 [PMID: 35728404]
  92. Structure. 2013 May 7;21(5):820-32 [PMID: 23602662]
  93. J Mol Biol. 2022 Jan 15;434(1):167228 [PMID: 34487789]
  94. Curr Opin Struct Biol. 2020 Feb;60:17-26 [PMID: 31790873]
  95. Immune Netw. 2022 Feb 14;22(1):e2 [PMID: 35291660]
  96. Elife. 2020 Nov 03;9: [PMID: 33138914]
  97. Proc Natl Acad Sci U S A. 2022 Jan 4;119(1): [PMID: 34937699]
  98. Cell. 2011 Nov 23;147(5):992-1009 [PMID: 22118458]
  99. Cancer Discov. 2022 Sep 2;12(9):2031-2043 [PMID: 35852417]
  100. Elife. 2021 Dec 07;10: [PMID: 34874008]
  101. Annu Rev Pathol. 2021 Jan 24;16:93-122 [PMID: 33497262]
  102. Front Oncol. 2021 Nov 18;11:762817 [PMID: 34868979]
  103. PLoS One. 2017 Jan 31;12(1):e0170953 [PMID: 28141819]
  104. Immunity. 2000 Aug;13(2):233-42 [PMID: 10981966]
  105. Mol Biosyst. 2009 Dec;5(12):1405-12 [PMID: 19593473]
  106. Cancer Lett. 2020 Nov 1;492:11-20 [PMID: 32745581]
  107. Cancers (Basel). 2022 Aug 11;14(16): [PMID: 36010865]
  108. F1000Res. 2016 Mar 31;5: [PMID: 27092248]
  109. Mol Immunol. 2019 Jun;110:3-12 [PMID: 29273393]
  110. Membranes (Basel). 2021 Mar 30;11(4): [PMID: 33808285]
  111. FEBS Lett. 2014 Apr 17;588(8):1193-204 [PMID: 24561196]
  112. Cell. 2016 Jul 28;166(3):651-663 [PMID: 27374333]
  113. Nat Rev Drug Discov. 2022 Nov;21(11):841-862 [PMID: 35974095]
  114. Biomedicines. 2022 Oct 26;10(11): [PMID: 36359228]
  115. J Cell Sci. 2014 Dec 1;127(Pt 23):4995-5005 [PMID: 25453114]
  116. Immunol Rev. 2013 Nov;256(1):107-17 [PMID: 24117816]
  117. Cold Spring Harb Perspect Med. 2020 May 1;10(5): [PMID: 31548218]
  118. Emerg Top Life Sci. 2020 Dec 11;4(3):307-318 [PMID: 32364240]
  119. Clin Exp Metastasis. 2021 Aug;38(4):373-399 [PMID: 34254215]
  120. Mol Ther Oncolytics. 2021 May 08;21:183-206 [PMID: 34027052]
  121. RNA. 2022 Jan;28(1):36-47 [PMID: 34772786]
  122. J Immunol. 2021 Aug 1;207(3):950-965 [PMID: 34282002]
  123. Cancers (Basel). 2022 Mar 08;14(6): [PMID: 35326534]
  124. Ann Rheum Dis. 2017 Jan;76(1):1-3 [PMID: 27566797]
  125. Front Immunol. 2018 Apr 06;9:684 [PMID: 29681902]
  126. Int J Biol Sci. 2022 Aug 1;18(13):5103-5122 [PMID: 35982902]
  127. Curr Drug Discov Technol. 2008 Dec;5(4):312-8 [PMID: 19075611]
  128. Curr Opin Cell Biol. 2011 Aug;23(4):370-6 [PMID: 21665455]
  129. Genes Dev. 2017 Sep 15;31(18):1827-1840 [PMID: 29051388]
  130. Trends Cell Biol. 2021 Feb;31(2):119-129 [PMID: 33248874]
  131. Front Immunol. 2018 Apr 05;9:527 [PMID: 29675018]
  132. Prostaglandins Other Lipid Mediat. 2015 Jul;120:17-20 [PMID: 25936481]
  133. Curr Opin Cell Biol. 2018 Feb;50:14-19 [PMID: 29438902]
  134. Curr Oncol Rep. 2018 Feb 7;20(1):8 [PMID: 29411148]
  135. Prog Biophys Mol Biol. 2014 Nov-Dec;116(2-3):158-64 [PMID: 25046855]
  136. Cell Rep. 2018 May 8;23(6):1794-1805 [PMID: 29742434]
  137. Front Cell Dev Biol. 2022 Mar 09;10:863850 [PMID: 35356286]
  138. Nat Rev Urol. 2013 Aug;10(8):441-51 [PMID: 23857181]
  139. Front Oncol. 2022 Mar 17;12:755053 [PMID: 35372044]
  140. Bioessays. 2018 Nov;40(11):e1800079 [PMID: 30188575]
  141. J Cell Biol. 2020 Oct 5;219(10): [PMID: 32777015]
  142. Cancers (Basel). 2022 Jun 10;14(12): [PMID: 35740532]
  143. Cell Microbiol. 2018 Oct;20(10):e12944 [PMID: 30123959]
  144. Annu Rev Cell Dev Biol. 2016 Oct 6;32:577-608 [PMID: 27576119]
  145. Cell. 2011 Mar 18;144(6):986-98 [PMID: 21414488]
  146. Front Cell Dev Biol. 2022 Apr 25;10:896305 [PMID: 35547815]
  147. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18238-42 [PMID: 17108085]
  148. Nucl Med Mol Imaging. 2021 Oct;55(5):225-236 [PMID: 34721715]
  149. Methods Mol Biol. 2022;2429:533-545 [PMID: 35507187]
  150. Protein Cell. 2012 Aug;3(8):564-70 [PMID: 22717983]
  151. Front Cell Dev Biol. 2019 Nov 21;7:299 [PMID: 31824949]
  152. Front Immunol. 2017 Jun 16;8:693 [PMID: 28670313]
  153. PLoS One. 2017 Dec 15;12(12):e0189545 [PMID: 29244882]
  154. J Immunol. 2011 Sep 15;187(6):3121-32 [PMID: 21844382]
  155. Cancer Metastasis Rev. 2012 Jun;31(1-2):195-208 [PMID: 22101652]
  156. Front Immunol. 2020 Dec 02;11:553967 [PMID: 33343560]
  157. Physiol Rev. 2021 Jan 1;101(1):147-176 [PMID: 32466724]
  158. Int J Mol Sci. 2020 Aug 17;21(16): [PMID: 32824618]
  159. Nature. 2009 Apr 9;458(7239):719-24 [PMID: 19360079]
  160. Nat Commun. 2022 Jan 19;13(1):392 [PMID: 35046403]
  161. J Exp Clin Cancer Res. 2020 May 18;39(1):89 [PMID: 32423420]
  162. Cancer Lett. 2019 Feb 1;442:445-452 [PMID: 30472185]
  163. Trends Cancer. 2021 Nov;7(11):1020-1032 [PMID: 34481763]
  164. Med Oncol. 2021 Jan 4;38(1):3 [PMID: 33394200]
  165. Nat Rev Cancer. 2016 Dec;16(12):775-788 [PMID: 27782134]
  166. Open Biol. 2021 Jun;11(6):210137 [PMID: 34129784]
  167. Proteomics. 2018 Mar;18(5-6):e1700167 [PMID: 29280568]
  168. Cell Rep. 2021 Apr 20;35(3):109009 [PMID: 33882319]
  169. Annu Rev Biochem. 2007;76:267-94 [PMID: 17506641]
  170. Trends Biochem Sci. 2021 Jul;46(7):535-549 [PMID: 33579564]
  171. Front Oncol. 2020 Dec 10;10:581457 [PMID: 33363012]
  172. Eur J Cancer. 2017 Mar;74:55-72 [PMID: 28335888]
  173. Curr Opin Cell Biol. 2021 Apr;69:48-54 [PMID: 33461072]
  174. Front Oncol. 2018 Jul 04;8:244 [PMID: 30023340]
  175. J Mol Biol. 2022 Jan 15;434(1):167151 [PMID: 34271007]
  176. Cell. 2020 Apr 16;181(2):346-361.e17 [PMID: 32302572]
  177. Curr Opin Chem Biol. 2019 Feb;48:26-33 [PMID: 30308468]
  178. iScience. 2020 Sep 1;23(9):101517 [PMID: 32927263]
  179. PLoS Genet. 2022 May 10;18(5):e1010210 [PMID: 35536863]
  180. J Biomed Mater Res B Appl Biomater. 2009 Feb;88(2):509-18 [PMID: 18481782]
  181. N Engl J Med. 2018 Jan 11;378(2):158-168 [PMID: 29320654]
  182. Cancer Discov. 2019 Jan;9(1):96-113 [PMID: 30361447]
  183. FEBS J. 2022 Jan;289(1):17-39 [PMID: 33583140]
  184. Immunol Rev. 2013 Jan;251(1):65-79 [PMID: 23278741]
  185. Elife. 2021 Dec 07;10: [PMID: 34874005]
  186. Nat Chem Biol. 2022 Dec;18(12):1298-1306 [PMID: 35761089]
  187. Nat Methods. 2019 Jan;16(1):20 [PMID: 30573843]
  188. Int J Mol Sci. 2022 Jul 29;23(15): [PMID: 35955517]
  189. Mol Cancer. 2021 Oct 11;20(1):131 [PMID: 34635121]
  190. Nat Rev Immunol. 2022 Mar;22(3):188-199 [PMID: 34230650]
  191. Nat Rev Mol Cell Biol. 2021 Mar;22(3):215-235 [PMID: 33169001]
  192. J Cell Sci. 2019 Jul 18;133(5): [PMID: 31235500]
  193. Genes Dev. 2019 Dec 1;33(23-24):1619-1634 [PMID: 31594803]
  194. Mol Cell Endocrinol. 2017 Jul 5;449:21-27 [PMID: 28115188]
  195. Cell Metab. 2019 Sep 3;30(3):434-446 [PMID: 31484055]
  196. Cancer Cell. 2021 Apr 12;39(4):463-465 [PMID: 33848477]
  197. Cold Spring Harb Perspect Med. 2020 Jul 1;10(7): [PMID: 31570380]
  198. Cold Spring Harb Perspect Biol. 2017 May 1;9(5): [PMID: 28096263]
  199. Cancers (Basel). 2020 Mar 27;12(4): [PMID: 32230806]
  200. Cancer Res. 2022 Aug 3;82(15):2661-2671 [PMID: 35856896]
  201. ChemMedChem. 2011 Jun 6;6(6):963-74 [PMID: 21520422]
  202. Cancer Cell. 2017 Sep 11;32(3):282-293 [PMID: 28898694]
  203. Nat Cell Biol. 2020 Oct;22(10):1187-1196 [PMID: 32929202]
  204. Cell. 2000 Jan 7;100(1):57-70 [PMID: 10647931]
  205. Genome Med. 2020 Mar 19;12(1):31 [PMID: 32192534]
  206. J Mol Biol. 2022 Jan 15;434(1):167216 [PMID: 34474085]
  207. Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13238-13247 [PMID: 32482873]
  208. Biochemistry (Mosc). 2019 Sep;84(9):1028-1039 [PMID: 31693462]
  209. Int J Mol Sci. 2020 Apr 10;21(7): [PMID: 32290245]
  210. Elife. 2020 Dec 28;9: [PMID: 33370234]
  211. Cancers (Basel). 2022 Jun 29;14(13): [PMID: 35804968]
  212. Dis Model Mech. 2018 Apr 19;11(4): [PMID: 29686035]
  213. Cancers (Basel). 2022 Aug 18;14(16): [PMID: 36010983]
  214. Cancers (Basel). 2022 Jan 07;14(2): [PMID: 35053446]
  215. Methods Mol Biol. 2017;1584:1-5 [PMID: 28255692]
  216. Biomed J. 2020 Feb;43(1):18-23 [PMID: 32200952]
  217. Curr Issues Mol Biol. 2022 Jan 21;44(2):505-525 [PMID: 35723321]
  218. Med Res Rev. 2021 May;41(3):1474-1498 [PMID: 33277742]
  219. Cancer Cell. 2017 Aug 14;32(2):135-154 [PMID: 28810142]
  220. Cells. 2018 Aug 09;7(8): [PMID: 30096862]
  221. Br J Cancer. 2021 Jan;124(1):58-65 [PMID: 33257836]
  222. Cancer Immunol Res. 2014 Nov;2(11):1023-33 [PMID: 25367977]
  223. Semin Immunol. 2021 Oct;57:101546 [PMID: 34887163]
  224. Cancer Discov. 2022 Jan;12(1):31-46 [PMID: 35022204]
  225. Front Mol Biosci. 2022 Jan 13;8:781981 [PMID: 35096966]
  226. Cell Rep. 2022 Mar 8;38(10):110490 [PMID: 35263600]
  227. Nat Rev Cancer. 2022 Feb;22(2):85-101 [PMID: 34611349]
  228. Mov Disord Clin Pract. 2021 Mar 02;8(3):299-310 [PMID: 33816657]
  229. Semin Cancer Biol. 2019 Feb;54:14-28 [PMID: 29175106]
  230. Nat Rev Mol Cell Biol. 2021 Oct;22(10):645-646 [PMID: 34282323]
  231. Genetika. 2016 Jul;52(7):745-60 [PMID: 29368838]
  232. Front Immunol. 2017 Dec 04;8:1708 [PMID: 29255465]
  233. Front Oncol. 2022 Aug 18;12:944487 [PMID: 36059616]
  234. Annu Rev Cell Dev Biol. 2016 Oct 6;32:303-325 [PMID: 27501450]
  235. Front Cell Dev Biol. 2021 Jun 21;9:631486 [PMID: 34235141]
  236. Science. 2020 Jun 19;368(6497):1386-1392 [PMID: 32554597]
  237. Immunol Rev. 2021 Jul;302(1):259-272 [PMID: 34013544]
  238. Nature. 2021 Sep;597(7876):329-331 [PMID: 34526702]
  239. Clin Transl Oncol. 2020 Dec;22(12):2141-2152 [PMID: 32447645]
  240. Science. 2007 Nov 16;318(5853):1108-13 [PMID: 17932254]
  241. Biochim Biophys Acta. 2013 Jul;1832(7):1070-8 [PMID: 23123598]
  242. Mol Cancer. 2019 Mar 30;18(1):64 [PMID: 30927925]
  243. Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13188-13193 [PMID: 29192024]
  244. Cancer Res. 2009 Feb 15;69(4):1259-62 [PMID: 19208831]
  245. Ann N Y Acad Sci. 2015 Sep;1349:83-95 [PMID: 25988664]
  246. Int J Mol Sci. 2020 May 25;21(10): [PMID: 32466338]
  247. Nature. 2021 Dec;600(7890):571 [PMID: 34931036]
  248. J Cell Sci. 2010 Feb 1;123(Pt 3):309-20 [PMID: 20130139]
  249. Science. 2013 Dec 6;342(6163):1243259 [PMID: 24311695]
  250. Biomed Res Int. 2014;2014:934038 [PMID: 25013812]
  251. Front Mol Biosci. 2021 Jul 05;8:684622 [PMID: 34291085]

Grants

  1. 22-15-00483/Russian Science Foundation

MeSH Term

Humans
Molecular Targeted Therapy
Neoplasms
Medicine
Tumor Microenvironment

Word Cloud

Created with Highcharts 10.0.0heterogeneityresultscancertargetedsupramoleculartumormicroenvironmentbiomoleculartumor-specificfeaturesTargetedunprecedentednon-reproducibilitypublishedfieldresearchrecentlycomespotlightshortreviewtryhighlightgeneralprinciplesorganizationevolutioncanceroustumorsobjectivelyleadenormousvariabilityconsequentlyirreproducibilityinvestigationalsoextremelyunfavorableeffectiveusemolecularlymedicineseeminglycomprehensivebackgroundsingletwocharacteristicscommontumors:clusterednatureinteractionsformationcondensatesdistinctivesuggestcanformbasisstrategiestherapiesCatastrophicObjectiveIrreproducibilityCancerResearchUnavoidableFailuresMolecularTherapiesSparklingHopeSupramolecularStrategiescondensatecell–cellinteractionsynapses

Similar Articles

Cited By